The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
Authors
Keywords
-
Journal
Frontiers in Molecular Neuroscience
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-03-28
DOI
10.3389/fnmol.2018.00082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mutant IDH1 regulates the tumor-associated immune system in gliomas
- (2017) Nduka M. Amankulor et al. GENES & DEVELOPMENT
- Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM
- (2017) Haitao Ge et al. INTERNATIONAL JOURNAL OF CANCER
- Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
- (2017) Gary Kohanbash et al. JOURNAL OF CLINICAL INVESTIGATION
- Correlation of immune phenotype with IDH mutation in diffuse glioma
- (2017) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression
- (2017) Luyan Mu et al. Frontiers in Immunology
- Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
- (2016) Weimin Wang et al. CELL
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
- (2016) Michele Ceccarelli et al. CELL
- miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
- (2016) Shaohua Xu et al. Nature Communications
- The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
- (2016) Chun-Te Wu et al. Scientific Reports
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth
- (2015) Wenchao Zhou et al. NATURE CELL BIOLOGY
- Mutational landscape and clonal architecture in grade II and III gliomas
- (2015) Hiromichi Suzuki et al. NATURE GENETICS
- Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors
- (2015) Jeanette E. Eckel-Passow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
- (2015) Alessandra Cesano Journal for ImmunoTherapy of Cancer
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Targeting immunosuppression for cancer therapy
- (2013) Cristina Ghirelli et al. JOURNAL OF CLINICAL INVESTIGATION
- DNA methylation: roles in mammalian development
- (2013) Zachary D. Smith et al. NATURE REVIEWS GENETICS
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
- (2013) D. Rohle et al. SCIENCE
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas
- (2012) Rezvan Ahmadi et al. JOURNAL OF NEURO-ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo
- (2011) Linda B. C. Bralten et al. ANNALS OF NEUROLOGY
- Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
- (2011) C. Hartmann et al. CLINICAL CANCER RESEARCH
- MGMT CpG island is invariably methylated in adult astrocytic and oligodendroglial tumors with IDH1 or IDH2 mutations
- (2011) Shani Mulholland et al. INTERNATIONAL JOURNAL OF CANCER
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
- (2011) M Fernanda Amary et al. JOURNAL OF PATHOLOGY
- Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome
- (2011) Twinkal C Pansuriya et al. NATURE GENETICS
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
- (2009) Koichi Ichimura et al. NEURO-ONCOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA hypomethylation in cancer cells
- (2009) Melanie Ehrlich Epigenomics
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now